Amber Kerstetter-Fogle,Eleftherios Sachlos,Thomas Bollenbach
Amber Kerstetter-Fogle
Will it be possible to generate kidney tissue from induced pluripotent stem cells for regenerative therapy? [0.03%]
有望利用诱导多能干细胞生成肾脏组织进行再生治疗吗？
Kenji Osafune
Kenji Osafune
Magali Cucchiarini,Henning Madry
Magali Cucchiarini
The inherent ethical challenge of first-in-human pluripotent stem cell trials [0.03%]
从第一例人的多能干细胞试验中体现的内在伦理挑战
Michelle G J L Habets,Johannes J M van Delden,Annelien L Bredenoord
Michelle G J L Habets
Amber E Kerstetter-Fogle
Amber E Kerstetter-Fogle
Comment
Regenerative medicine. 2013 Nov;8(6):696-7. DOI: 2013
Matthew D Li,Harold Atkins,Tania Bubela
Matthew D Li
Aim: To provide a comprehensive analysis of clinical trials (CTs) listed in worldwide registries involving new applications for stem cell-based treatments and account for the role of industry. ...
Applications of human hematopoietic stem cells isolated and expanded from different tissues in regenerative medicine [0.03%]
来源于不同组织的造血干细胞的分离与扩增在再生医学中的应用研究
Chaturvedula Tripura,Gopal Pande
Chaturvedula Tripura
Bone marrow transplantation is a well-established stem cell-based therapy for the management of malignant and nonmalignant hematological disorders. In addition to the bone marrow, therapeutic hematopoietic stem cells (HSCs) can also be obta...
Kate E Hawkins,Tyson V Sharp,Tristan R McKay
Kate E Hawkins
Regenerative medicine relies on harnessing the capacity of stem cells to grow, divide and differentiate safely and predictably. This may be in the context of expanding stem cells in vitro or encouraging their expansion, mobilization and cap...
Mark J Post,Nastaran Rahimi,Vincenza Caolo
Mark J Post
Vascularization of engineered tissues is critical for success. Adequate and physiologically regulated blood supply is important for viability of the implanted tissue but even more important for the proper function of parenchymal cells, whic...
Early evaluation and value-based pricing of regenerative medicine technologies [0.03%]
再生医疗技术的早期评估和基于价值的定价
Florian Koerber,Bernd Rolauffs,Wolf Rogowski
Florian Koerber
Since the first pioneering scientists explored the potential of using human cells for therapeutic purposes the branch of regenerative medicine has evolved to become a mature industry. The focus has switched from 'what can be done' to 'what ...